4.4 Long-term safety and off-target effects Emerging reports link GLP-1RAs to rare ocular adverse events, including NAION ( 5 Conclusion In conclusion, the expanding body of evidence supports that GLP-1RAs offer a multifaceted approach to ocular therapeutics by targeting key molecular pathways involved in retinal neuroprotection, mitochondrial regulation, inflammation, vascular remodeling, and angiogenesis
Sassoon DJ, Tune JD, Mather KJ, Noblet JN, Eagleson MA, Conteh AM, Sturek JT, Goodwill AG
GLP-1 weight-loss medications may be available for a $50 monthly copay The Medicare GLP-1 Bridge Program is now active
Farsad-Naeimi, A., et al
It is the most clinically studied of the three, with topical trials showing collagen, fine-line, and skin-density changes, and a large body of in-vitro work on gene expression and wound healing
At 5 mg/mL, 1 unit = 50 mcg